A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Key Inclusion Criteria: * A histologically or cytologically confirmed diagnosis of advanced or metastatic solid cancer refractory to standard treatment, for which no standard therapy is available or for which the patient refuses standard therapy. * Measurable disease or evaluable, nonmeasurable disease. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2. * Hemoglobin ≥ 9.0 g/dL, ANC \> 1500/uL and platelet count ≥ 100,000/uL. * AST/serum glutamic oxaloacetic transaminase (SGOT) and ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 × the upper limit of normal (ULN). * Bilirubin ≤ ULN. * Serum creatinine ≤ 1.5 × ULN. * Potassium, magnesium and calcium (corrected calcium when serum albumin levels are abnormal) within the normal range. * Additional criteria exist. Key Exclusion Criteria: * 12-lead ECG demonstrating a mean QTcF \> 450 msec (triplicate assessment) at the Screening Visit or history/evidence of long QT syndrome. * History of acute coronary syndromes, including unstable angina, coronary angioplasty, or stenting, within the past 24 weeks. * Use of concomitant medications that prolong the QT/QTc interval, as assessed by the Investigator, within 14 days prior to first dose of study drug. * Use of concomitant medication that is a strong CYP3A inhibitor or inducer within 14 days prior to first dose of study drug. * Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. * Un…